Top View
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin
- Xpovio® (Selinexor) – New Indication
- Selinexor Supportive Care Guidelines in R/R MM
- Labeling Sections: Thrombocytopenia [See Warnings and Precautions (5.1)]
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
- Effect of Prior Treatments on Selinexor, Bortezomib, and Dexamethasone In
- Integrated Safety Profile of Selinexor in Multiple Myeloma
- The Multiple Myeloma Drug Market Paul Wilcock and Rachel Webster Credit: Gino De Graaf/Alamy Stock Photo
- Karyopharm Therapeutics Address: 85 Wells Avenue, 2Nd Floor, Newton, MA 02459 Phone: 617-658-0600 Email: [email protected] Date of Request: November 12, 2020
- Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer
- Selinexor Combined with Cladribine, Cytarabine, and Filgrastim In
- Selinexor Plus Low Dose Dexamethasone in Patients with Penta Exposed and Triple Class-Refractory MM
- The Enhancement of Anti-Tumor Activities of Selinexor When Combined with Immune Checkpoint Inhibitors Trinayan Kashyap, Karyopharm Therapeutics
- Karyopharm Announces FDA Approval of XPOVIOTM (Selinexor) for the Treatment of Patients with Relapsed Or Refractory Multiple Myeloma
- Age and Frailty Subgroup Analyses from the Phase 3 BOSTON Study
- IN a RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION Author(S): Christine Chen, Et Al
- Selinexor Plus Pomalidomide and Low Dose Dexamethasone (Spd) in Patients with Relapsed Or Refractory Multiple
- Selinexor, Pomalidomide, and Dexamethasone in Patients with Relapsed Or Refractory Multiple Myeloma
- Targeting Nuclear Export in Chronic Lymphocytic Leukemia
- Phase 1 Study of Selinexor Plus Carfilzomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
- A Phase 1B/2 Study of Selinexor, Carfilzomib, and Dexamethasone (Skd) in Relapsed / Refractory Multiple
- Click EHA2021 Abstracts
- Emerging Patterns in the Development of Medicines in Paediatric Oncology
- Selinexor) Tablets, for Oral Use Loss May Occur
- Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (Srd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- Results of the Pivotal STORM Study
- XPO1-Dependent Nuclear Export As a Target for Cancer Therapy Nancy G
- Consensus Recommendations for the Clinical Management of Patients with Multiple Myeloma Treated with Selinexor
- (Spd) in Patients with Relapsed Or Refractory Multiple Myeloma
- Nuclear Transport Inhibition in Acute Myeloid Leukemia: Recent Advances and Future Perspectives
- An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed Or Refractory Acute Myeloid Leukemia
- KPT-330) in Patients with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) and Prior Therapy with Abiraterone And/Or Enzalutamide
- XPOVIO (Selinexor) MULTI-DISCIPLINE REVIEW
- Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ)
- Selinexor (Nexpovio®) in Combination with Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma (MM)
- FDA Briefing Document Oncologic Drugs Advisory Committee Meeting
- INSIGHTS INTO MULTIPLE MYELOMA October 2019 HOW to NAVIGATE THIS REPORT
- Targeting Nuclear Import and Export in Hematological Malignancies
- Isatuximab-Irfc (Sarclisa®) Office Administration Infusion Center Administration Home Infusion Administration Outpatient Facility Administration
- Selinexor (KPT-330) Has Antitumor Activity Against Anaplastic Thyroid
- Selinexor (Xpovio) Reference Number: CP.PHAR.431 Effective Date: 07.16.19 Last Review Date: 08.20 Line of Business: Commercial, HIM, Medicaid Revision Log